Arcadia Biosciences, Inc.
RKDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | 0.03 | -0.06 |
| FCF Yield | -119.48% | -395.16% | -216.23% | -121.43% |
| EV / EBITDA | -0.53 | 0.29 | 0.82 | 0.12 |
| Quality | ||||
| ROIC | -32.84% | -35.96% | -54.45% | -88.92% |
| Gross Margin | 41.27% | 51.19% | 17.75% | -28.44% |
| Cash Conversion Ratio | 2.23 | 1.09 | 0.90 | 1.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.06% | -13.07% | -2.62% | 1,892,577.26% |
| Free Cash Flow Growth | 36.97% | -8.90% | 47.72% | 17.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 0.96 | 1.26 | 0.92 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,776.30 |
| Efficiency | ||||
| Inventory Turnover | 3.28 | 1.11 | 2.63 | 1.96 |
| Cash Conversion Cycle | 109.77 | 236.37 | 144.79 | 200.42 |